title: Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide.
authors.affiliation: Department of Hematology, CHU of Liège, Liège, Belgium.
authors.forename: Jo
authors.initials: J
authors.lastname: Caers
authors.forename: Kaoutar
authors.initials: K
authors.lastname: Hafraoui
authors.forename: Aurore
authors.initials: A
authors.lastname: Keutgens
authors.forename: Jean-Hubert
authors.initials: JH
authors.lastname: Caberg
authors.forename: Frederic
authors.initials: F
authors.lastname: Lambert
authors.forename: Francoise
authors.initials: F
authors.lastname: Tassin
authors.forename: Yves
authors.initials: Y
authors.lastname: Beguin
mesh_terms: D000369:Aged, 80 and over; D000753:Anemia, Refractory / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D001853:Bone Marrow / Q000473:pathology; D004913:Erythrocytes, Abnormal / Q000473:pathology*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D000077269:Lenalidomide; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013922:Thrombocytosis / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D007155:Immunologic Factors; D013792:Thalidomide; D000077269:Lenalidomide